How Skandor engages.
AI Governance Assurance Review
3–4 weeks
An independent assessment of whether your AI governance framework is defensible under EU AI Act scrutiny and whether your leadership has adequate visibility of AI risk.
Designed for pharmaceutical and life sciences organisations deploying AI in clinical, commercial, or operational environments.
Scope includes
AI Act high-risk classification review for active systems
DPIA adequacy assessment for AI-driven data processing
Governance framework gap analysis
C-level reporting quality review
Senior management accountability mapping
Written assessment
Privacy & AI Governance De-risking
3–9 months
Senior advisory embedded into transformation programmes digital platform deployments, AI tool integrations, cloud migrations, EHDS data sharing arrangements ensuring GDPR obligations, AI Act conformity, and clinical governance are managed as integrated risk, not addressed after the fact.
Scope includes
Privacy and AI risk embedded into programme governance
Article 9 health data treatment and transfer analysis
Third-party and vendor AI governance oversight
DPIA execution for novel AI processing activities
Cross-border data flow assessment and documentation
Regulator-ready documentation and audit trail support
Senior Management Assurance
Annual retainer
Sustained senior advisory for Audit committees, and C-suite executives on privacy and AI governance accountability. Provides the independent perspective and the preparedness that regulators increasingly expect to see evidenced at the top.
Scope includes
Quarterly C-suite or audit committee briefings
Senior manager accountability and attestation support
Management information quality review on AI and privacy risk
Regulatory horizon monitoring for pharma and life sciences
Priority access for emerging regulatory questions
Preparation for supervisory authority engagements